Abstract:Objective: To construct a neovessel-targeted PEGylated liposome formulation to promote the efficiency of the intracellular delivery of antitumor reagents. Methods: The complex of (alanyl-prolyl-arginyl-prolyl-glycine, APRPG) and (lysine-glycine-glycine, KGG) were synthesized by using fluorenylmethyloxycarbonyl ( FMOC) solid-phase synthesis method. The neovessel-targeted polyethylene glycol liposomes (T-PEG-LP) and polyethylene glycol-liposomes (PEG-LP) were prepared by thin film sonication-dispersion method. Mean particle size and particle size distribution of targeted PEGylated liposomes were determined using laser particle sizer. The morphology of liposomes was observed under transmission electron microscope (TEM). To evaluate the affinity between targeted liposomes and tumor cells or vessel endothelial cells, rhodamine-labelled neovessel targeted fluorescent polyethylene glycol liposomes ( T-F-PEG-LP) and fluorescent polyethylene glycol liposomes (F-PEG-LP) were synthesized by using thin film sonication-dispersion method. The specific binding of T-F-PEG-LP and F-PEG-LP with human umbilical vein endothelial cell ( HUVEC) and human lung cancer A549 cells was detected by fluorospectrophotometer examination and flow cytometry analysis. Polyethylene-glycol paclitaxel liposomes (PEG-PTX-LP) and neovessel-targeted polyethylene glycol paclitaxel liposomes (T-PEG-PTX-LP) were also prepared. The cellular uptakes of PEG-PTX-LP and T-PEG-PTX-LP by HUVEC and A549 cells were detected by fluorospectrophotometer examination and flow cytometry analysis. Results: TEM showed that both the T-PEG-LP PEG-LP shaped regular round or a little elliptic. Laser particle sizer indicated the average size of particles was less than 100 nm. T-F-PEG-LP had stronger affinity to HUVEC and A549 cells compared with F-PEG-LP(P<0.05). The uptakes of T-PTG-PTX-LP by HUVEC and A549 cells were higher than that of Taxol solusion and PEG-PTX-LP( P<0.05 ). Conclusion: The constructed formulation of neovessel-targeted PEGylated liposomes might be a novel effective carrier for anti-tumor reagents.

in vitro Model for Targeting Tumor Vasculature Using Immunoliposome

Targeting Tumor Cells by Natural Anti-Carbohydrate Antibodies Using Rhamnose-Functionalized Liposomes.

Study on Tumor Targeting Ability of Neovessel-Targeted PEGylated Liposomes

Antiangiogenic Targeting Liposomes Increase Therapeutic Efficacy for Solid Tumors*

Preparation of a novel neovessel-targeted PEGylated liposome formulation

A Dual Drug-Loaded Tumor Vasculature-Targeting Liposome for Tumor Vasculature Disruption and Hypoxia-Enhanced Chemotherapy

Antibody-directed Targeting of Tumor Vasculature

[Cationic Liposomes Loaded with Doxorubicin Targeting to the Tumor Neovasculature in Vitro].

PHSCNK-Modified and Doxorubicin-Loaded Liposomes As a Dual Targeting System to Integrin-Overexpressing Tumor Neovasculature and Tumor Cells.

The Targeted-liposome Delivery System of Antitumor Drugs

rated liposome targeting a v b 3-expressing tumor cells in vitro and in vivo

Integrin αvβ3-targeted liposomal drug delivery system for enhanced lung cancer therapy

Preparation of Adriamycin Liposomes Conjugated with VEGF and Its Targeting Action on Human Tumor-Derived Vascular Endothelial Cells in Vitro

Homologous tumor cell membrane vesicles active preferential self-recognition of tumor cells in vitro

Antitumor efficacy of doxorubicin encapsulated in neovasculature targeting liposomes

A Novel Anti-Vegf165 Monoclonal Antibody-Conjugated Liposomal Nanocarrier System: Physical Characterization and Cellular Uptake Evaluation in Vitro and in Vivo.

Enhanced antitumor and anti-metastasis by VEGFR2-targeted doxorubicin immunoliposome synergy with NK cell activation

A Synthetic Peptide Mediated Active Targeting of Cisplatin Liposomes to Tie2 Expressing Cells.

Targeted delivery of RGD-modified liposomes encapsulating both combretastatin A-4 and doxorubicin for tumor therapy: in vitro and in vivo studies.

Effects of surface displayed targeting ligand GE11 on liposome distribution and extravasation in tumor.

Application of liposomes as carriers of anti-tumor drugs